Healthcare stocks were rising premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7% and the iShares Biotechnology ETF (IBB) 0.3% higher.
Amneal Pharmaceuticals (AMRX) stock was up more than 2% after the company said interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.
BioCardia (BCDA) has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction, the company said. Shares of BioCardia were up more than 33% pre-bell.